AUSTRALASIA

One of the largest pharmaceutical companies in the Australasia region, with a comprehensive portfolio of medicines comprising Regional Brands, including prescription and over-the-counter products, as well as Sterile Focus Brands. A widely-accredited manufacturing facility is operated in Australia, producing finished dose form (“FDF”) solids, liquids and semi-solids as well as packaging for third party contract manufacturing for domestic and export markets.

Key Countries

Australia
New Zealand

KEY BRANDS

Brand		Therapeutic category
Circadin		Sleeping aid
Eltroxin/Eutroxsig/Oroxine		Thyroid hormone replacement range
Maltofer		Iron supplement
Ural		Womens’ health
Xylocaine & Adrenaline		Regional anaesthetic

NUMBER OF PERMANENT EMPLOYEES

538

June 2021

531

June 2020

STATISTICS

Number of products launched:

2

(2020: 2)

Number of product recalls:

Nil

(2020: 2)

Average staff turnover:

8%

(2020: 9%)

Number of work-related fatalities:

Nil

(2020: Nil)

Sales representatives:

74

(2020: 70)

Revenue	2021 R’million	2020 (CER) R’million	Change %
Total Commercial Pharmaceuticals	4 867	4 623	5
Regional Brands	4 113	3 876	6
Sterile Focus Brands	754	747	1
Manufacturing – FDF	554	430	29
Total	5 421	5 053	7

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.

The Australian and New Zealand pharmaceutical market combined, grew 1,9% and was valued at AUD20,7 billion MAT* to May 2021.

Source: IQVIA – August 2020
*MAT = Moving annual total